Showing results (11-20 of 937) with videos related to

Sort By:
Pageof 94
Current Pharmaceutical Design|April 1, 2011
The effect of sex/gender on cardiovascular pharmacologyFlavia Franconi, Ciriaco Carru, Walter Malorni, et al.
Current Opinion in HIV and AIDS|October 9, 2013
Optimization and simplification of antiretroviral therapy for adults and childrenNathan Ford, Charles Flexner, Stefano Vella, et al.
Antioxidants & Redox Signaling|September 8, 2007
Redox features of the cell: a gender perspectiveWalter Malorni, Ilaria Campesi, Elisabetta Straface, et al.
BMC Pharmacology & Toxicology|September 24, 2013
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cellsMaria Luisa Dupuis, Alessandro Ascione, Lucia Palmisano, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitorsPaola Matarrese, Lucrezia Gambardella, Antonio Cassone, et al.
BMC Infectious Diseases|September 2, 2024
The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort studyAbel Gedefaw, Birkneh Tilahun Tadesse, Yifru Berhan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 15, 2018
Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World CohortMatteo Ruggeri, Silvia Coretti, Federica Romano, et al.
AIDS (London, England)|June 19, 2012
The history of antiretroviral therapy and of its implementation in resource-limited areas of the worldStefano Vella, Bernard Schwartländer, Salif Papa Sow, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 26, 2002
In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicinMothanje Barbara Lucia, Sergio Rutella, Giuseppe Leone, et al.
Pharmacoeconomics|November 1, 2018
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER DataAndrea Marcellusi, Raffaella Viti, Loreta A Kondili, et al.
Pageof 94